Objective To investigate the clinical effect of azacitidine combined with CAG regimen(aclarubicin+cytarabine+granulocyte colony stimulating factor)in the treatment of patients with acute myeloid leukemia.Methods A total of 68 patients with acute myeloid leukemia admitted in Xinyang Central Hospital from January 2020 to June 2023 were selected as the research objects and divided into control group and observation group by random number table method,with 34 cases in each group.The control group was treated with CAG regimen,and the observation group was treated with azacitidine on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group,the difference was statistically significant(P＜0.05).After treatment,the white blood cell count and platelet count in the observation group were higher than those in the control group,and the hemoglobin level was lower than that in the control group,the differences were statistically significant(P＜0.05).After treatment,the CD3+,CD4+and CD4+/CD8+in the observation group were higher than those in the control group,and the CD8+was lower than that in the control group(P＜0.05).After treatment,the levels of vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF)in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reaction between the two groups(P＞0.05).Conclusion The azacitidine combined with CAG regimen in the treatment of patients with acute myeloid leukemia has significant clinical effect.It can improve blood routine indexes and immune function,and reduce the levels of VEGF and bFGF with high safety.
维普
万方数据